May 09, 2024
BRANFORD, Conn. --(BUSINESS WIRE)--May 9, 2024-- Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the three months ended March 31, 2024 , and provided a business
Feb 16, 2024
BRANFORD, Conn. --(BUSINESS WIRE)--Feb. 16, 2024-- Azitra, Inc. (NYSE American: AZTR) (the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced the closing of its previously announced public offering of
Feb 13, 2024
BRANFORD, Conn. --(BUSINESS WIRE)--Feb. 13, 2024-- Azitra, Inc. (NYSE American: AZTR) (“Company”), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced the pricing of an underwritten public offering of 16,667,000 shares of